Pfizer releases positive Hympavzi Phase III results in hemophilia

US pharm giant Pfizer (NYSE: PFE) today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed.

Already approved in key markets for severe hemophilia A or B patients without inhibitors, Pfizer is hoping to expand use of Hympavzi (marstacimab) to those with inhibitors after reporting success in a Phase III study.